Given that the high activity of quizartinib against AML is overcome by development of resistance, we previously examined whether switching between FLT3 inhibitors with different means of resistance (different resistance mutations) could be a useful approach to prolong resistance-free survival in AML. Here, FLT3 is linked to acute myeloid leukemia.